Centessa Pharmaceuticals (CNTA) Other Non-Current Assets (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Other Non-Current Assets data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 31.99% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 31.99% YoY) and the FY2025 annual result came in at $1.4 million, down 29.62% from the prior year.
• Other Non-Current Assets declined to $1.3 million in Q1 2026 per CNTA's latest filing, from $1.4 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $6.0 million in Q1 2023 and bottomed at $619000.0 in Q1 2022.
• The 5-year median for Other Non-Current Assets is $1.9 million (2025), against an average of $2.0 million.
• The widest annual swing landed in 2023, when Other Non-Current Assets soared 875.77%; it then tumbled 68.82% in 2024.
• Tracing CNTA's Other Non-Current Assets over 5 years: stood at $1.9 million in 2022, then soared by 35.85% to $2.6 million in 2023, then slipped by 19.89% to $2.0 million in 2024, then dropped by 29.62% to $1.4 million in 2025, then dropped by 11.11% to $1.3 million in 2026.
• Per Business Quant, the three latest CNTA Other Non-Current Assets figures stand at $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.6 million (Q3 2025).

Peer Comparison